Prognostic importance of temporal changes in resting heart rate in heart failure patients: An analysis of the CHARM program

European Heart Journal

Volumn 36, Issue 11, 2015, Pages 669-675

  Vazir, Ali ^a,b   Claggett, Brian ^a   Jhund, Pardeep ^a,c   Castagno, Davide ^d   Skali, Hicham ^a   Yusuf, Salim ^e   Swedberg, Karl ^b,f,g   Granger, Christopher B ^h   McMurray, John J V ^c   Pfeffer, Marc A ^a   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heart failure; Heart rate; Outcome research

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; VASODILATOR AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RESTING HEART RATE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; HEART RATE; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; RISK ASSESSMENT; TETRAZOLES; TREATMENT OUTCOME;

EID: 84925271236     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu401     Document Type: Article

References (20)

1. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD, Investigators C. Association of heart rate and outcomes in a broad spectrumof patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012;59:1785-1795.
2. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebocontrolled trial. Lancet 2010;376:886-894.
3. Fox K, Borer JS,CammAJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, Heart RateWorking G. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-830.
4. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryden L, Atlas Study Group. Assessment of treatment with l, survival. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-48.
5. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004;26:637-644.
6. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
7. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I, Investigators S. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012;59:1938-1945.
8. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794.
9. Nauman J, Janszky I, Vatten LJ, Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011;306:2579-2587.
10. Jouven X, Empana JP, Escolano S, Buyck JF, Tafflet M, Desnos M, Ducimetiere P. Relation of heart rate at rest and long-term (.20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009;103:279-283.
11. Paul L, Hastie CE, LiWS, HarrowC, Muir S, Connell JM,DominiczakAF, McInnesGT, Padmanabhan S. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010;55:567-574.
12. PfefferMA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, Investigators C, Committees. Effects of candesartan on mortality and morbidity in patientswith chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
13. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776.
14. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
15. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
16. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75.
17. Kaye DM, LambertGW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23:570-578.
18. Black A, Murray L, Cardwell C, Smith GD, McCarron P. Secular trends in heart rate in young adults, 1949 to 2004: analyses of cross sectional studies. Heart 2006;92: 468-473.
19. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005;26: 2259-2268.
20. Cullington D, Goode KM, Zhang J, Cleland JG, Clark AL. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail 2014;2: 213-220.